Hi all,
among the various intervention for longevity, we knows that cancer screening deserve a very important factor, whereby prevention is relatively limited (other than, staying healthy not to add additional risk factors).
So any longevity protocol must take into account cancer screening as a periodic practice and that can fall into different specific medical areas (es: blood in stoll for colon cancer) but also broad sceeening such as MRIs (very interesting Ezra.com with full body AI/differential analysis, I plan to fly to London to try) and most recently Circulating Tumor DNA (otherwise known as liquid biopsy).
Liquid biopsy is very cool, because it just requires a blood exams, can be repeated periodically (let’s say every 6 months?) and it starts to be more accessible (managed to find a lab also in italy, usually late comer country).
Let’s come to the key point: how to evaluate the quality and sophistication of a liquid biopsy CtDNA analysis service?
The only service I found in italy present a tech specs of screening 50 genes for mutations https://onconext.it/en/onconext-liquid/onconext-liquid-technical-reports/ .
Learning of liquid biopsy I understand latest frontier are going multi-omics with cfRNA, proteomics, and methylation patterns too.
But also for CtDNA, how to evaluate if 50 genes are enough, and if the sensibility of detection is up the latests standard?
I wish this thread to get input and evaluation on how to introduce and evaluate properly liquid biopsy as part of periodic cancer screening in a longevity protocol.
Fabio